Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational Uncertainty

Postpartum depression is a clinically significant perinatal mental health condition with consequences for maternal functioning, infant care, family dynamics, and healthcare engagement. Although psychotherapy, psychosocial support, and conventional antidepressants remain central to treatment, important therapeutic gaps persist, including the delayed onset of conventional antidepressants, variable or incomplete treatment response, tolerability concerns, and barriers to timely access to specialized perinatal mental healthcare, particularly when rapid symptom improvement is clinically needed. Zuranolone is an oral neuroactive steroid and positive allosteric modulator of gamma-aminobutyric acid type A receptors, administered as a short 14-day treatment course. Pivotal placebo-controlled trials demonstrated rapid short-term improvement in depressive symptoms among adults with postpartum depression, supporting its regulatory approval as an indication-specific treatment. However, the available evidence is strongest for short-term symptom reduction in trial populations with severe depressive symptoms, with the primary efficacy endpoint assessed at day 15 and follow-up extending only through day 45. Important uncertainties remain regarding durability of response, relapse, retreatment, breastfeeding outcomes, functional recovery, comparative effectiveness, access, cost, equity, and real-world implementation. In addition, zuranolone was not approved as a broad treatment for major depressive disorder, underscoring the need to avoid extrapolating postpartum depression findings to all depressive populations. Overall, zuranolone should be understood as a meaningful but evidence-bounded innovation in perinatal psychopharmacology, whose clinical value will depend on careful patient selection, safety counseling, follow-up, equitable access, and continued evidence generation.